 |
|
Preliminary Assessment of Inhaled Nitric Oxide for Acute Vaso-occlusive Crisis in Pediatric Patients With Sickle Cell Disease
Debra L. Weiner, MD, PhD;
Patricia L. Hibberd, MD, PhD;
Peter Betit, RRT;
Andrew B. Cooper, PhD;
Christine A. Botelho, MPH;
Carlo Brugnara, MD
JAMA. 2003;289:1136-1142.
Context Vaso-occlusion is central to the painful crises and acute and chronic organ damage in sickle cell disease. Abnormal nitric oxide–dependent regulation of vascular tone, adhesion, platelet activation, and inflammation contributes to the pathophysiology of vaso-occlusion. Nitric oxide may have promise as a mechanism-of-disease–based therapy for treatment of vaso-occlusion.
Objective To explore the efficacy and safety of inhaled nitric oxide (INO) for treatment of vaso-occlusive crisis in pediatric patients.
Design Prospective, double-blind, placebo-controlled, randomized clinical trial with enrollment between September 1999 and October 2001.
Setting Urban, tertiary care children's hospital in the United States.
Participants Twenty patients aged 10 to 21 years with sickle cell disease and severe acute vaso-occlusive crisis.
Intervention Patients were randomly assigned to receive INO (80 ppm with 21% final concentration of inspired oxygen; n = 10), or placebo (21% inspired oxygen; n = 10) for 4 hours.
Main Outcome Measures Change in pain at 4 hours of inhalation compared with preinhalation pain, measured on a 10-cm visual analog scale (VAS); secondary outcome measures were pain over 6 hours, parenteral narcotic use over 24 hours, duration of hospitalization, blood pressure, oxygen saturation, and methemoglobin concentration.
Results Preinhalation VAS pain scores were similar in the INO and placebo groups (P = .80). The decrease in VAS pain scores at 4 hours was 2.0 cm in the INO group and 1.2 cm in the placebo group (P = .37). Repeated-measures analysis of variance for hourly pain scores showed a 1-cm/h greater reduction in the INO group than the placebo group (P = .02). Morphine use over 6 hours was significantly less in the INO group (mean cumulative use, 0.29 vs 0.44 mg/kg; P = .03) but was not different over 4 hours (0.26 vs 0.32 mg/kg; P = .21) or 24 hours (0.63 vs 0.91 mg/kg; P = .15). Duration of hospitalization was 78 and 100 hours in the INO and placebo groups, respectively (P = .19). No INO toxicity was observed.
Conclusions Results of this exploratory study suggest that INO may be beneficial for acute vaso-occlusive crisis. These preliminary results warrant further investigation.
Author Affiliations: Pediatric Emergency (Dr Weiner), Clinical Research Program (Drs Hibberd and Cooper and Ms Botelho), Respiratory Care (Mr Betit), and Department of Laboratory Medicine (Dr Brugnara), Children's Hospital Boston, and Harvard Medical School (Drs Weiner, Hibberd, and Brugnara and Mr Betit), Boston, Mass.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
A randomized, controlled clinical trial of ketoprofen for sickle-cell disease vaso-occlusive crises in adults
Bartolucci et al.
Blood 2009;114:3742-3747.
ABSTRACT
| FULL TEXT
NKT cells mediate pulmonary inflammation and dysfunction in murine sickle cell disease through production of IFN-{gamma} and CXCR3 chemokines
Wallace et al.
Blood 2009;114:667-676.
ABSTRACT
| FULL TEXT
Evolution of Novel Small-Molecule Therapeutics Targeting Sickle Cell Vasculopathy
Kato and Gladwin
JAMA 2008;300:2638-2646.
ABSTRACT
| FULL TEXT
Novel Small Molecule Therapeutics for Sickle Cell Disease: Nitric Oxide, Carbon Monoxide, Nitrite, and Apolipoprotein A-I
Kato
ASH Education Book 2008;2008:186-192.
ABSTRACT
| FULL TEXT
Nitric Oxide in the Pulmonary Vasculature
Coggins and Bloch
Arterioscler. Thromb. Vasc. Bio. 2007;27:1877-1885.
ABSTRACT
| FULL TEXT
Protective effects of S-nitrosoalbumin on lung injury induced by hypoxia-reoxygenation in mouse model of sickle cell disease
de Franceschi et al.
Am. J. Physiol. Lung Cell. Mol. Physiol. 2006;291:L457-L465.
ABSTRACT
| FULL TEXT
Red blood cells express a functional endothelial nitric oxide synthase
Kleinbongard et al.
Blood 2006;107:2943-2951.
ABSTRACT
| FULL TEXT
Extrapulmonary effects of inhaled nitric oxide: role of reversible s-nitrosylation of erythrocytic hemoglobin.
McMahon and Doctor
Proc Am Thorac Soc 2006;3:153-160.
ABSTRACT
| FULL TEXT
Anaesthesia for peculiar cells--a century of sickle cell disease
Firth
Br J Anaesth 2005;95:287-299.
ABSTRACT
| FULL TEXT
An Evidence-Based Approach to the Treatment of Adults with Sickle Cell Disease
Lottenberg and Hassell
ASH Education Book 2005;2005:58-65.
ABSTRACT
| FULL TEXT
Arterial Stiffness and Wave Reflections in Patients With Sickle Cell Disease
Lemogoum et al.
Hypertension 2004;44:924-929.
ABSTRACT
| FULL TEXT
Protective Effects of No-Albumin and Albumin on Lung Injury Induced by Hypoxia/Reoxygenation in a Mouse Model of Sickle Cell Disease.
De Franceschi et al.
ASH ANNUAL MEETING ABSTRACTS 2004;104:3580-3580.
ABSTRACT
Better Reporting of Harms in Randomized Trials: An Extension of the CONSORT Statement
Ioannidis et al.
ANN INTERN MED 2004;141:781-788.
ABSTRACT
| FULL TEXT
Inhaled Nitric Oxide: A Selective Pulmonary Vasodilator: Current Uses and Therapeutic Potential
Ichinose et al.
Circulation 2004;109:3106-3111.
FULL TEXT
Sickle Cell Disease
Buchanan et al.
ASH Education Book 2004;2004:35-47.
ABSTRACT
| FULL TEXT
Inhaled Nitric Oxide Therapy for the Vaso-occlusive Crisis in Sickle Cell Disease
Thiagarajan
AAP Grand Rounds 2003;9:50-51.
FULL TEXT
Inhaled Nitric Oxide Is Beneficial for Sickle Cell Crisis
JWatch Emergency Med. 2003;2003:2-2.
FULL TEXT
|
